Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Breast cancer
FAST NOVEMBER: A Phase II Randomized Trial of a 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
University of Utah is evaluating the optimal duration for whole breast radiotherapy—with both 5- and 9-day schedules using a brachytherapy device—in early-stage adjuvant breast cancer.
NCT06961955 - New trial
Breast cancer
Prospective Randomized Trial of Two Versus One Week Accelerated Radiotherapy (PRATO)
This randomized trial compares a one-week radiotherapy regimen (2600 cGy in 5 fractions) with a two-week schedule (3200 cGy in 10 fractions plus a concomitant tumor bed boost to 3600 cGy) to evaluate side effects,…
NCT06960707 - New trial
Breast cancer
Phase I Trial: Adjuvant Alpha-lactalbumin Vaccine in High-Risk TNBC
Case Comprehensive Cancer Center is evaluating the safety and optimal dosing of an α‑lactalbumin vaccine combined with zymosan in a Phase I trial targeting non-metastatic triple-negative breast cancer patients at…
NCT04674306 - New trial
Non-small cell lung cancer
Phase II Trial of HLX43 (Anti-PD-L1 ADC) in Advanced NSCLC
Henlius is launching a global, open-label Phase II study to explore the optimal dosing and evaluate the efficacy, safety, and tolerability of HLX43 in patients with advanced/metastatic NSCLC, including those with…
NCT06907615 - New trial
Non-small cell lung cancer
A Phase I, Single-Arm, Single-Institution Study Evaluating Neoadjuvant Chemoimmunotherapy with Immunosensitizing Radiation for Borderline Resectable NSCLC
UMB is exploring whether adding three fractions of SBRT immediately before three cycles of chemoimmunotherapy with nivolumab can enhance surgical outcomes in borderline resectable NSCLC. Patients will be followed for…
NCT06800339 - New trial
Non-small cell lung cancer
Expanded Access Program of Taletrectinib in Advanced ROS1+ NSCLC
This expanded access program from Nuvation Bio provides taletrectinib—a ROS1 and NTRK inhibitor—for patients with advanced or metastatic ROS1-positive NSCLC who aren't candidates for approved therapies, allowing…
NCT06841874 - New trial
Non-small cell lung cancer
Phase 3 Trial of Ivonescimab vs Pembrolizumab in High PD-L1 Metastatic NSCLC
Summit Therapeutics is leading a multicenter, double-blind Phase 3 study comparing ivonescimab—a PD-1/VEGF bispecific antibody—with pembrolizumab in first-line therapy for metastatic NSCLC patients whose tumors…
NCT06767514 - New trial
Pancreatic cancer
A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma
Johns Hopkins is investigating the optimal dosing and safety of AGEN2373 combined with balstilimab alongside either GVAX or a mutated KRAS peptide vaccine, aimed at enhancing neoadjuvant and adjuvant treatment…
NCT06782932 - New trial
Pancreatic cancer
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
This early phase I trial from OHSU is investigating multiple targeted agents (cobimetinib, olaparib, onvansertib, azenosertib, AZD5305, and tremelimumab) in advanced pancreatic cancer through pre- and post-treatment…
NCT04005690 - New trial
Pancreatic cancer
Phase I/II Clinical Trial of Ontegimod and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma: Reprogramming Tumor-associated Myeloid Cells
Investigators at WashU are testing whether CD11b agonism can reprogram the tumor microenvironment to overcome resistance to checkpoint immunotherapy in advanced, unresectable pancreatic adenocarcinoma. The open-label…
NCT06904378 - New trial
Prostate cancer
BURN Study: Buffered Lidocaine in Reducing Pain From Prostate Biopsy
This phase I/II trial evaluates whether buffered lidocaine during prostate biopsy can reduce procedural pain compared to standard lidocaine. The study, focusing on resectable prostate cancer patients, is led by the…
NCT06661902 - New trial
Prostate cancer
Evaluation of Ultralow Dose PET Imaging for Detecting PSMA Expression
This study from Nuclear Imaging Institute is assessing an ultralow dose PET imaging technique using 18F-DCFPyL to detect prostate cancer with significantly reduced radiation exposure. Healthy volunteers and patients…
NCT06904313 - New trial
Prostate cancer
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Antelope Surgical Solutions is evaluating a single peripheral IV bolus dose of AS1986NS as a PSMA-directed fluorescent imaging agent for prostate cancer.
NCT06906471 - New trial
Prostate cancer
4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy
This trial evaluates whether 4-aminopyridine can accelerate recovery from peripheral nerve injuries sustained during surgery for localized prostate cancer, comparing an investigational potassium channel blocker…
NCT03701581 - New trial
Melanoma
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Advanced Melanoma
This trial is evaluating a single dose of CD40L-augmented TIL therapy in advanced melanoma patients—including those with rare subtypes—after failure of standard treatment, with lymphodepletion and a short course of…
NCT06961357 - New trial
Melanoma
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
This phase 2, single‐arm trial is evaluating the combination of pembrolizumab and metronomic cyclophosphamide in patients with refractory, unresectable non-ocular stage III/IV melanoma. Sponsored by UC Irvine, the…
NCT06771544 - New trial
Lymphoma
A Phase II Study of Pirtobrutinib in Combination With Rituximab in Newly Diagnosed Marginal Zone Lymphoma: A Risk Adapted Approach
This trial evaluates the efficacy of pirtobrutinib, a BTK inhibitor, in combination with rituximab for patients with newly diagnosed marginal zone lymphoma using a risk-adapted approach. Sponsored by the University…
NCT06390956 - New trial
Lymphoma
Phase II Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
This phase II study will evaluate epcoritamab—a bispecific CD20/CD4 antibody—as a first-line treatment for newly diagnosed MZL, with patients receiving up to 12 cycles over 28-day cycles for a maximum of 3 years.
NCT06796998 - New trial
Ovarian cancer
A Phase 1b Study of BCL-XL Degrader DT2216 in Combination With Weekly Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer
Dana Farber is investigating the maximum tolerable dose of DT2216—a selective BCL-xL degrader—administered with weekly paclitaxel in patients with recurrent platinum-resistant ovarian cancer, using a Bayesian Optimal…
NCT06964009 - New trial
Ovarian cancer
Phase II Trial: Mirvetuximab Soravtansine & Olaparib Maintenance in Recurrent Ovarian Cancer
University of Colorado, Denver is evaluating a maintenance therapy combining mirvetuximab soravtansine—a FOLR1-directed ADC—with olaparib in patients with platinum-sensitive, recurrent high-grade ovarian, peritoneal,…
NCT05887609 - New trial
Ovarian cancer
Phase 2 Study of Relacorilant Combo in Advanced Ovarian Cancer (BELLA)
This Phase 2 trial evaluates the safety and efficacy of intermittent relacorilant combined with nab-paclitaxel and bevacizumab in patients with advanced, platinum-resistant ovarian cancer, focusing on high-grade…
NCT06906341 - New trial
Bladder and urothelial cancer
HERO Trial: Phase I Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents in Localized Bladder Cancer
This trial explores a neoadjuvant combo of intravesical romidepsin and durvalumab in cisplatin-ineligible, muscle-invasive bladder cancer patients, testing escalating doses of the HDAC inhibitor to boost…
NCT06963346 - New trial
Bladder and urothelial cancer
Phase 1/2 Study of Intravesical Sacituzumab Tirumotecan in Intermediate-risk NMIBC
Merck is launching an open-label study to assess the safety, tolerability, and optimal dosing of intravesically administered Sacituzumab Tirumotecan in participants with intermediate-risk, low-grade, recurrent NMIBC.…
NCT06637423 - New trial
Brain and CNS tumors
Phase I Trial of Anti-GARP CAR-T in Recurrent High-Grade Glioma
Ohio State is evaluating the safety, optimal dosing, and initial efficacy of anti-GARP CAR-T cell therapy in patients with recurrent grade III/IV gliomas through a treatment protocol that includes apheresis, surgery…
NCT06964737 - New trial
Brain and CNS tumors
Feasibility Study Using FUS with Oral Etoposide in Pediatric Diffuse Midline Glioma
Columbia is assessing whether focused ultrasound can safely open the blood brain barrier to boost oral etoposide delivery in children with progressive diffuse midline glioma, potentially enhancing tumor uptake while…
NCT05762419 - New trial
Brain and CNS tumors
Randomized Study of DOC1021 Dendritic Cell Immunotherapy in Combination with Standard of Care for Newly Diagnosed Adult Glioblastoma
This study evaluates whether adding DOC1021 dendritic cell immunotherapy with pIFN to the standard regimen of surgery, temozolomide, and radiation can improve survival in newly diagnosed IDH-wt glioblastoma patients…
NCT06805305 - New trial
Thyroid cancer
Neoadjuvant Treatment With Zanzalintinib for Advanced Thyroid Cancer
MD Anderson is conducting a trial to assess the safety and effectiveness of zanzalintinib (100 mg daily) followed by surgery in advanced thyroid cancers—both medullary (non-RET mutant) and non-medullary subtypes.
NCT06959511 - New trial
Thyroid cancer
Phase 2 Open Label Study of XL092 as First Line Therapy in Radioiodine Refractory Differentiated Thyroid Cancer
This phase II trial is evaluating XL092, a tyrosine kinase inhibitor, as first-line therapy for advanced thyroid cancer that no longer responds to radioiodine treatment. Patients receive daily oral dosing with…
NCT06959641 - New trial
Thyroid cancer
Comparison of I-124 PET/CT to I-123 Imaging for Metastatic Thyroid Cancer
This single-arm prospective study compares the efficacy of I-124 PET/CT with traditional I-123/I-131 imaging in metastatic thyroid cancer patients, using an oral dose of I-124 followed by PET/CT scanning 20–28 hours…
NCT06961084 - New trial
Multiple myeloma
Phase 1 Trial: SX-682 Combination with Standard of Care in Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute is evaluating SX-682—a CXCR1/2 inhibitor—in combination with carfilzomib, daratumumab-hyaluronidase, and dexamethasone for patients with secretory multiple myeloma that has relapsed or…
NCT06622005
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.